

Attorney Docket No.: 4318.234-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al.

Confirmation No: 8501

COPY OF PAPERS  
ORIGINALLY FILED

Serial No.: 10/025,648

Group Art Unit: 1751

Filed: December 19, 2001

Examiner: To be assigned

For: Amylase Variants

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box DD  
Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD  
Commissioner for Patents  
Washington, DC 20231

on June 12, 2002.

Julie Tabarovsky  
(name of person mailing paper)

J. Tabarovsky  
(signature of person mailing paper)

RECEIVED  
JUN 27 2002  
TC 1700

RECEIVED  
JUL 17 2002



Attorney Docket No.: 4318.234-US

COPY OF PAPERS  
ORIGINALLY FILED  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Bisgaard-Frantzen et al.

Confirmation No: 8501

Serial No.: 10/025,648

Group Art Unit: 1751

Filed: December 19, 2001

Examiner: To be assigned

For: Amylase Variants

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)**

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references was filed in US application no. 09/902,188 filed July 10, 2001, the benefit of which is claimed under 35 USC 120.

The references are as follows:

1. PCT WO 95/10603
2. PCT WO 95/21247
3. PCT WO 95/26397
4. PCT WO 94/02597
5. PCT WO 91/16423
6. PCT WO 94/18314

RECEIVED  
JUN 27 2002  
TC 1700




7. Tsukamoto, A., et al., Biochem. and Biophys. Res. Com., Vol. 151, No.1, pgs. 25-31 (1988).
8. Estell, D.A., et al., The Jour. Biol. Chem., Vol. 260, No. 11, pgs. 6518-6521 (1985).
9. PCT WO 91/00353
10. FR 2 676 456
11. FR 2 665 178
12. Abstract - Dialog, File 351, Derwent WPI, Dialog Accession No. 007176688
13. Suzuki, Y., et al., The Jour. of Biol. Chem., Vol. 264, No. 32, pgs. 18933-18938 (1989)
14. PCT WO 95/35382
15. Chemical Abstracts, Vol. 112, No. 15, The Abstract No. 135178r, pg. 347
16. Chemical Abstracts, Vol. 108, No. 11, The Abstract No. 90927h, pg. 325
17. Chemical Abstracts, Vol. 112, No. 19, The Abstract No. 174785f, pg. 350
18. US Patent No. 4,600,693
19. PCT WO 87/00202

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,



Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Date: June 12, 2002

